The HEADWIND Study - Part 2

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

May 27, 2021

Study Completion Date

May 28, 2021

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
OTHER

Controlled hypoglycaemic state while driving

Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.

Trial Locations (1)

Unknown

Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Bern

All Listed Sponsors
collaborator

ETH Zurich

OTHER

collaborator

University of St.Gallen

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT04569630 - The HEADWIND Study - Part 2 | Biotech Hunter | Biotech Hunter